U.S. Water Utilities Stock News

Great Lakes Dredge & Dock Corporation ( NASDAQ:GLDD ), is not the largest company out there, but it received a lot of...

Recent performance snapshot for TPG (TPG) With no single headline event driving attention to TPG (TPG), recent trading performance and fundamentals provide the main reference points for assessing how the stock currently sits. See our latest analysis for TPG. At a share price of $67.27, TPG has had a 90 day share price return of 22.53%, while the 1 year total shareholder return of 6.27% contrasts with a much stronger 3 year total shareholder return of 135.12%, suggesting that earlier momentum...

Hinge Health (HNGE) is back in focus after its recent trading, with the stock closing at US$43.76 and showing mixed short term moves, including a small 1 day gain and declines over the past month. See our latest analysis for Hinge Health. That 1 day share price return of 0.99% comes after weaker recent momentum, with 7 day, 30 day, 90 day and year to date share price returns all in decline. This suggests enthusiasm has cooled in the short term even as the broader story continues to...

Newmark Group recently arranged one of Philadelphia’s largest industrial leases, a 1.4 million-square-foot commitment by DrinkPAK at The Bellwether District, and brokered the US$425,000,000 sale of The Shops at Skyview retail center in Queens, while also securing a US$289,000,000 acquisition loan for the buyer. These high-profile transactions underline Newmark’s role in large-capital commercial real estate deals across industrial and retail, potentially reinforcing its positioning in key...

A recent independent study found that Ameren Corporation’s operations in Missouri and Illinois generated more than US$20.70 billion in annual economic output, supported 55,200 jobs and contributed US$920 million in taxes to state and local governments. The report underscores how Ameren’s ongoing investments not only power customers but also anchor regional development by supporting thousands of new jobs and broader economic expansion in the communities it serves. With Ameren’s...

Recently, SkyWater Technology reported quarterly revenue of US$150.74 million, a year-over-year increase of 60.7%, with earnings per share rising to US$0.24 from US$0.08, exceeding analyst expectations. This combination of rapid revenue expansion and consistent earnings outperformance points to strengthening business momentum that is drawing increased investor attention. Next, we’ll examine how SkyWater’s stronger-than-expected earnings and revenue growth may influence its investment...

In Q4 2025, Heartland Advisors highlighted Lamar Advertising Company (NASDAQ:LAMR) as a top contributor after a solid Q3 report, favorable outlook, and increased capital returns through share buybacks and a higher dividend. Investor attention has also focused on the potential for higher political advertising during the 2026 mid-term election cycle to support Lamar’s profits and cash flow. Next, we’ll explore how management’s use of share buybacks and a higher dividend may influence Lamar’s...

In advance of its upcoming quarterly report, Fulton Financial is now expected by Wall Street analysts to post earnings of $0.52 per share and revenue of $335 million, both higher than the same period a year ago. These projections, which also include slight shifts in efficiency ratio and net interest margin, are shaping investor expectations around how effectively Fulton is managing costs and its core banking profitability. We’ll now explore how the expectation of higher quarterly earnings...

In January 2026, NWPX Infrastructure announced the first commercial use of its patent-pending Permalok Radial Bending Joint (RBJ) technology, supplying 5,764 linear feet of curved steel casing pipe for Tampa Bay Water’s South Hillsborough Pipeline microtunneling project, which includes 18 underground crossings. This curved RBJ system enables pipeline routes to bend around existing utilities and structures, potentially lowering construction disruption through fewer shafts, smaller sites, and...

In recent days, Pilgrim's Pride drew fresh attention after Grupo Santander upgraded the stock from Neutral to Outperform and it was highlighted among leading food stocks for 2026. This recognition comes despite earlier commentary pointing to modest historical revenue growth and expectations for flat sales over the next year, underscoring how analyst opinions can still influence sentiment. We’ll now examine how this upgrade and Pilgrim's Pride’s inclusion among top food picks may reshape the...

Why Mike Portegello’s Appointment Matters for ePlus (PLUS) ePlus (PLUS) has brought Mike Portegello onto its Board of Directors and key committees, a move that puts long experience in accounting, finance, and capital markets closer to the company’s decision making. For you as an investor, this kind of board appointment is less about headlines and more about what it could mean for financial oversight, risk controls, and how the company evaluates growth and capital allocation decisions over...

If you are wondering whether Exelixis at US$45.44 is still a sensible entry or more of a hold, the key question is how its current price compares with its underlying value. The stock has logged returns of 2.9% over the past week, 9.2% over the past month, 4.3% year to date, 24.3% over one year, 174.9% over three years and 113.1% over five years. This naturally raises questions about risk, timing and what is already priced in. Recent attention around Exelixis has centered on its position in...

In early January 2026, Upstream Bio, Inc. presented at the 44th Annual J.P. Morgan Healthcare Conference, while analysts initiated and upgraded coverage around its asthma candidate verekitug and the upcoming Phase 2 VALINAT readout. The combination of growing physician enthusiasm for long-acting TSLP inhibition and expectations for the VALINAT data has sharpened investor focus on Upstream Bio’s clinical pipeline. Against this backdrop, we’ll examine how physician interest in verekitug and...

In recent weeks, Mineralys Therapeutics reported stronger-than-expected third-quarter 2025 results while advancing its lead drug lorundrostat toward a New Drug Application for uncontrolled hypertension and chronic kidney disease. At the same time, senior executives executed pre-arranged Rule 10b5-1 stock sales as lorundrostat gained recognition in JAMA’s Research of the Year Roundup and the company presented at the 15th Annual LifeSci Partners Corporate Access Event. Against this backdrop,...

On January 15, 2026, Galaxy Digital Inc. announced it had completed ERCOT’s Large Load Interconnection Study and secured approval for an additional 830 megawatts of computing demand at its Helios data center campus in West Texas, lifting total approved and contracted power capacity at the site to over 1.6 gigawatts. This substantial power upgrade underpins Galaxy’s ambition to build a multi-tenant, multi-campus, multi-gigawatt platform for AI and high-performance computing workloads, using...

If you are wondering whether First Solar's share price still makes sense after recent moves, you are not alone. This article is designed to help you judge the current value with a clear framework. At a last close of US$243.64, the stock has had a 1.1% decline over the past week, a 5.8% decline over the past month, an 11.2% decline year to date, yet a 27.6% return over 1 year, 47.7% over 3 years and 126.6% over 5 years. This naturally raises questions about how much of the story is already in...

Antero Midstream (AM) has kept its quarterly cash dividend at $0.225 per share, alongside fourth quarter share repurchases and new senior notes offerings that reshape how cash flows between the company and its investors. See our latest analysis for Antero Midstream. At a share price of US$17.84, Antero Midstream has seen a 7 day share price return of 2.94% while its 1 year total shareholder return of 15.25% and 5 year total shareholder return above 200% reflect gradually building momentum...

If you are wondering whether Rezolve AI's recent run makes the stock look cheap or stretched, this article walks through what the current price could imply about its value. The shares last closed at US$4.62, with returns of 24.5% over 7 days, 55.6% over 30 days, 61.0% year to date and 53.5% over 1 year, while the 3 year return sits at a 54.2% decline. Recent price moves have come as Rezolve AI continues to attract attention in the AI and software space, where investor interest can quickly...

In recent months, Brady Corporation reported solid quarterly results, with five-year compounded annual revenue growth of 7.5% and earnings per share increasing 15.7% annually. These figures highlight that Brady’s offerings continue to appeal to customers even as its core organic revenue growth slowed to 1.6% over the past two years. While strong long-term sales and earnings trends underscore the effectiveness of Brady’s product portfolio and execution, the recent slowdown in organic growth...

STAAR Surgical recently reshaped its board after shareholders rejected a proposed merger with Alcon, adding three investor-affiliated directors while CEO Stephen Farrell stepped down from the board but remains in the role until January 31, 2026. This shift hands greater influence to major shareholder Broadwood Partners and its allies, signaling potential changes in governance priorities and capital allocation for the standalone company. With Broadwood-backed directors now on the board, we’ll...

If you are wondering whether Easterly Government Properties is attractively priced or not, you are in the right place. This article is built around helping you make sense of what the current share price might imply. The stock last closed at US$22.87, with returns of 1.1% over the past week, 2.7% over the past month, a 7.3% gain year to date, and declines of 13.2% over 1 year, 24.4% over 3 years, and 43.5% over 5 years. This can signal shifting views on both its potential and its...

H.B. Fuller FY 2025 earnings snapshot H.B. Fuller (FUL) has wrapped up FY 2025 with fourth quarter revenue of US$894.8 million and basic EPS of US$0.55, setting the tone for a year where earnings momentum and margin progression were in focus for investors. The company has seen quarterly revenue move from US$917.9 million in Q3 2024 to the US$788.7 million to US$898.1 million range across the first three quarters of 2025, while basic EPS shifted from US$1.01 in Q3 2024 to US$0.24, US$0.77 and...

If you are wondering whether Planet Labs PBC is still reasonably priced after its recent run, this article walks through what the current share price might be implying about the business. The stock closed at US$28.28, with returns of 26.0% over 7 days, 58.2% over 30 days, 38.6% year to date, and a very large gain over 1 year that is more than 7x. Recent coverage has focused on Planet Labs PBC's role in satellite powered Earth observation and how its data products are being used across areas...

If you have been wondering whether Omnicom Group's share price still reflects its underlying business, this article walks through what the current numbers actually say about value. The stock last closed at US$80.84, with returns of 2.6% over the past 7 days, 0.2% over the past 30 days, a 0.6% decline year to date and a 2.3% decline over the past year. This is set against gains of 8.8% over 3 years and 52.6% over 5 years. Recent coverage has focused on how global advertising and marketing...